A bull-bear debate ends in favor of the optimists
Aurinia Pharmaceuticals, a hotly debated biotech company, proved its many doubters wrong yesterday when the company’s lupus treatment met its goals in a pivotal trial.
As STAT’s Adam Feuerstein reports, Aurinia’s drug demonstrated a response rate of 41% after one year, significantly beating the 22.5% seen in the control arm. There was one death reported in the drug arm compared to five deaths in the control group, a key finding that will help dispel concerns about the treatment’s safety.
Aurinia’s stock price doubled on the news, rewarding the company’s faithful investors and stinging the many who were betting against it.
Read more.
As STAT’s Adam Feuerstein reports, Aurinia’s drug demonstrated a response rate of 41% after one year, significantly beating the 22.5% seen in the control arm. There was one death reported in the drug arm compared to five deaths in the control group, a key finding that will help dispel concerns about the treatment’s safety.
Aurinia’s stock price doubled on the news, rewarding the company’s faithful investors and stinging the many who were betting against it.
Read more.
No hay comentarios:
Publicar un comentario